AR124303A1 - Inhibidores de irak4 - Google Patents
Inhibidores de irak4Info
- Publication number
- AR124303A1 AR124303A1 ARP210103432A ARP210103432A AR124303A1 AR 124303 A1 AR124303 A1 AR 124303A1 AR P210103432 A ARP210103432 A AR P210103432A AR P210103432 A ARP210103432 A AR P210103432A AR 124303 A1 AR124303 A1 AR 124303A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- cycloalkyl
- formula
- pharmaceutically acceptable
- Prior art date
Links
- 229940127590 IRAK4 inhibitor Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 C(O)Me Chemical group 0.000 abstract 2
- 101100134925 Gallus gallus COR6 gene Proteins 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 abstract 1
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 abstract 1
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente memoria descriptiva se refiere a compuestos químicos de fórmula (1), y sales farmacéuticamente aceptables de estos, que inhiben IRAK4 y en consecuencia tienen una posible utilidad en medicina. Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable de este, donde: R¹ se selecciona entre los restos de fórmula (2) y (3); R² se selecciona entre los restos de fórmula (4), (5) y (6); R³ y R⁴ se seleccionan cada uno independientemente entre H, Me, Et, alquilo C₁₋₆ sustituido opcionalmente y cicloalquilo C₃₋₆ sustituido opcionalmente; Y es N(Me)COMe, N(R⁵)COMe, N(Me)COR⁶, N(R⁵)COR⁶, CONMe₂ o un N-heterociclo de 5 miembros tal como 1,2,3-triazol y Z es H, Me, Et y alquilo C₁₋₆ sustituido opcionalmente; o Y y Z se combinan para formar un anillo de 4, 5 ó 6 miembros sustituido opcionalmente; X se selecciona entre OR⁷ y NR⁸R⁹; R⁵ se selecciona entre H, alquilo C₁₋₆ sustituido opcionalmente y cicloalquilo C₃₋₆ sustituido opcionalmente; R⁶ se selecciona entre alquilo C₁₋₆ sustituido opcionalmente, cicloalquilo C₃₋₆ sustituido opcionalmente y N-heterociclo saturado de 5 ó 6 miembros sustituido opcionalmente; R⁷ es Me, Et, i-propilo, n-propilo, ciclopropilo, ciclobutilo, un anillo de 4, 5 ó 6 miembros que contiene un heteroátomo seleccionado entre O y N, grupo cicloalquilo C₃₋₆ o alquilo C₁₋₆ sustituido opcionalmente; R⁸ y R⁹ se seleccionan independientemente entre H, Me y alquilo C₁₋₆ sustituido opcionalmente o juntos forman un cicloalquilo C₃₋₆ sustituido opcionalmente o un anillo de 4, 5 ó 6 miembros sustituido opcionalmente que contiene un heterátomo adicional seleccionado entre O y N; donde los sustituyentes opcionales de Z, R³, R⁴, R⁵, R⁶, R⁷, R⁸ y R⁹, cuando están presentes, se seleccionan independientemente entre OH, alquilo C₁₋₃, alcoxi C₁₋₃, C(O)Me, amino, NHMe, NMe₂, F o Cl. Reivindicación 10: Una composición farmacéutica que comprende un compuesto de fórmula (1) de acuerdo con cualquier reivindicación anterior y al menos un excipiente farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063199160P | 2020-12-10 | 2020-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124303A1 true AR124303A1 (es) | 2023-03-15 |
Family
ID=79230946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103432A AR124303A1 (es) | 2020-12-10 | 2021-12-10 | Inhibidores de irak4 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11866405B2 (es) |
| EP (1) | EP4259632A1 (es) |
| JP (1) | JP2023552838A (es) |
| KR (1) | KR20230118153A (es) |
| CN (1) | CN116583285A (es) |
| AR (1) | AR124303A1 (es) |
| AU (1) | AU2021395816B2 (es) |
| CA (1) | CA3203569A1 (es) |
| CL (1) | CL2023001662A1 (es) |
| CO (1) | CO2023007624A2 (es) |
| CR (1) | CR20230264A (es) |
| DO (1) | DOP2023000119A (es) |
| EC (1) | ECSP23050553A (es) |
| IL (1) | IL303356A (es) |
| MX (1) | MX2023006816A (es) |
| PE (1) | PE20240684A1 (es) |
| TW (1) | TW202237612A (es) |
| UY (1) | UY39561A (es) |
| WO (1) | WO2022122876A1 (es) |
| ZA (1) | ZA202306848B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023152349A1 (en) * | 2022-02-14 | 2023-08-17 | Astrazeneca Ab | Irak4 inhibitors |
| WO2023227703A1 (en) * | 2022-05-26 | 2023-11-30 | Astrazeneca Ab | Solid forms of heterocyclylamides as irak4 inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2802641C (en) | 2010-07-13 | 2019-03-12 | Nidhi Arora | Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators |
| CA2822166C (en) | 2010-12-20 | 2019-10-29 | Merck Serono S.A. | Indazolyl triazole derivatives as irak inhibitors |
| JP6503338B2 (ja) | 2013-03-15 | 2019-04-17 | バイオマリン ファーマシューティカル インコーポレイテッド | Ｈｄａｃ阻害剤 |
| BR112016015983A2 (pt) | 2014-01-10 | 2017-08-08 | Aurigene Discovery Tech Ltd | Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica |
| ES2718552T3 (es) | 2014-04-04 | 2019-07-02 | Pfizer | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de IRAK4 |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| WO2016174183A1 (en) | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| BR112018000624A2 (pt) | 2015-07-15 | 2018-09-18 | Aurigene Discovery Technologies Limited | compostos de indazol e azaindazol como inibidores de irak-4 |
| CA2992408A1 (en) | 2015-07-15 | 2017-01-19 | Aurigene Discovery Technologies Limited | Substituted aza compounds as irak-4 inhibitors |
| CN109153665B (zh) | 2016-03-03 | 2021-10-15 | 拜耳医药股份有限公司 | 新的2-取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途 |
| US10059708B2 (en) | 2016-04-26 | 2018-08-28 | Northwestern University | Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r) |
| US20190125736A1 (en) | 2016-06-01 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases |
| WO2018234342A1 (en) | 2017-06-21 | 2018-12-27 | F. Hoffmann-La Roche Ag | ISOINDOLINONE DERIVATIVES AS MODULATORS OF IRAK4 |
| WO2018234343A1 (en) | 2017-06-21 | 2018-12-27 | F. Hoffmann-La Roche Ag | BENZOFURANES AS MODULATORS OF IRAQ4 |
| KR20220042132A (ko) | 2019-06-27 | 2022-04-04 | 바이오젠 엠에이 인코포레이티드 | 2h-이미다졸 유도체 및 질환 치료에서 그의 용도 |
| EP3990454A1 (en) | 2019-06-27 | 2022-05-04 | Biogen MA Inc. | Imidazo[1,2-a]pyridinyl derivatives and their use in the treatment of disease |
-
2021
- 2021-12-01 US US17/457,249 patent/US11866405B2/en active Active
- 2021-12-09 CR CR20230264A patent/CR20230264A/es unknown
- 2021-12-09 AU AU2021395816A patent/AU2021395816B2/en active Active
- 2021-12-09 WO PCT/EP2021/084916 patent/WO2022122876A1/en active Application Filing
- 2021-12-09 JP JP2023535016A patent/JP2023552838A/ja active Pending
- 2021-12-09 PE PE2023001857A patent/PE20240684A1/es unknown
- 2021-12-09 EP EP21836097.2A patent/EP4259632A1/en active Pending
- 2021-12-09 CN CN202180082181.5A patent/CN116583285A/zh active Pending
- 2021-12-09 CA CA3203569A patent/CA3203569A1/en active Pending
- 2021-12-09 KR KR1020237023107A patent/KR20230118153A/ko unknown
- 2021-12-09 IL IL303356A patent/IL303356A/en unknown
- 2021-12-09 TW TW110145977A patent/TW202237612A/zh unknown
- 2021-12-09 MX MX2023006816A patent/MX2023006816A/es unknown
- 2021-12-10 AR ARP210103432A patent/AR124303A1/es unknown
- 2021-12-10 UY UY0001039561A patent/UY39561A/es unknown
-
2023
- 2023-06-08 CL CL2023001662A patent/CL2023001662A1/es unknown
- 2023-06-09 DO DO2023000119A patent/DOP2023000119A/es unknown
- 2023-06-09 CO CONC2023/0007624A patent/CO2023007624A2/es unknown
- 2023-07-05 EC ECSENADI202350553A patent/ECSP23050553A/es unknown
- 2023-07-05 ZA ZA2023/06848A patent/ZA202306848B/en unknown
- 2023-11-02 US US18/500,155 patent/US20240182479A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CR20230264A (es) | 2023-07-26 |
| CA3203569A1 (en) | 2022-06-16 |
| PE20240684A1 (es) | 2024-04-10 |
| UY39561A (es) | 2022-06-30 |
| AU2021395816A1 (en) | 2023-07-13 |
| US20220185817A1 (en) | 2022-06-16 |
| US20240182479A1 (en) | 2024-06-06 |
| DOP2023000119A (es) | 2023-07-09 |
| CO2023007624A2 (es) | 2023-06-30 |
| ZA202306848B (en) | 2024-04-24 |
| CL2023001662A1 (es) | 2024-01-12 |
| ECSP23050553A (es) | 2023-08-31 |
| US11866405B2 (en) | 2024-01-09 |
| MX2023006816A (es) | 2023-06-21 |
| WO2022122876A1 (en) | 2022-06-16 |
| KR20230118153A (ko) | 2023-08-10 |
| CN116583285A (zh) | 2023-08-11 |
| AU2021395816B2 (en) | 2024-04-04 |
| EP4259632A1 (en) | 2023-10-18 |
| IL303356A (en) | 2023-08-01 |
| TW202237612A (zh) | 2022-10-01 |
| JP2023552838A (ja) | 2023-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124303A1 (es) | Inhibidores de irak4 | |
| AR118374A1 (es) | Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos | |
| AR113964A1 (es) | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| PE20231066A1 (es) | Agonistas heterociclicos de glp-1 | |
| PE20190980A1 (es) | Compuestos terapeuticos y metodos para utilizarlos | |
| AR116464A1 (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| AR111874A1 (es) | Derivados de pirimidina | |
| AR123962A1 (es) | Inhibidores de interleucina-17 | |
| AR123701A1 (es) | Preparación de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 | |
| AR116905A1 (es) | Derivados de ácido pirrolidino-2-carboxílico para tratar el dolor y afecciones relacionadas con el dolor | |
| AR123884A1 (es) | Compuestos moduladores del cftr, composiciones y usos de estos | |
| AR120169A1 (es) | Derivados de 2-azaespiro[3.4]octano como agonistas de m4 | |
| AR119728A1 (es) | Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2 | |
| AR123700A1 (es) | Preparación de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 | |
| AR100126A1 (es) | Activadores de herg policíclicos | |
| AR119341A1 (es) | Profármacos de moduladores del receptor de nmda | |
| AR088003A1 (es) | Derivados de metansulfonamida sustituidos con amina como ligandos del receptor de vanilloide | |
| AR121554A1 (es) | Azálidos de urea inmunoduladores | |
| AR120329A1 (es) | Inhibidores de pequeñas moléculas de mutante g12c de kras | |
| AR110252A1 (es) | Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam | |
| AR115403A1 (es) | DERIVADOS DE N-PIRIMIDIN-4-IL-PIRIDINA-3-SULFONAMIDA COMO MODULADORES DE LOS CANALES DE SODIO (NaV1.7) Y EL USO DE LOS MISMOS EN EL TRATAMIENTO DEL DOLOR | |
| AR127185A1 (es) | Compuestos de pirazolopiridina como inhibidores de tam | |
| AR123543A1 (es) | DERIVADOS DE 2-(3-PIRIDIN-2-IL-4-QUINOLIN-4-IL-PIRAZOL-1-IL)-ACETAMIDA COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO TRANSFORMANTE b-1 / ALK5 |